FDA Pivotal-Study Feedback Receives for Alpha1H in NMIBC
“The Oncology Division at FDA has been extraordinarily helpful and collaborative, and we celebrate this latest interaction as a major step forward for the Alpha1H program, getting us closer than ever to making this therapy available to patients in the shortest time possible. We are grateful for the FDA’s support and look forward to next steps, to implement this feedback into the clinical program and begin study enrollment, says Hamlet CEO, Catharina Svanborg. The Hamlet team she has assembled includes the consultants from Target Health in the US and InClino in Europe.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.